Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.
Source:: Reuters – Business News
Newswire
- [ October 21, 2024 ] Leaders in The News: Trump Media, Siyata Mobile, New World Solutions, LogicMark News Feed
- [ October 21, 2024 ] Trump Media (NASDAQ: DJT) Expands TV Streaming Delivery Network to Multi-site Operation Newsmakers
- [ October 21, 2024 ] T-Mobile to Offer Siyata’s (NASDAQ: SYTA) New Mission Critical Over 5G Cellular Radios for First Responders Newsmakers
- [ October 14, 2024 ] Leaders in The News: BigBear.ai, Luminar, New World Solutions, Tevogen Bio News Feed
- [ October 14, 2024 ] Tevogen Bio (NASDAQ: TVGN) Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024 Newsmakers
- [ October 14, 2024 ] BigBear.ai (NYSE: BBAI) Awarded 5-Year Production Contract Valued at $165 Million to Deliver the U.S. Army’s Global Force Information Management – Objective Environment (GFIM-OE) Newsmakers
- [ October 11, 2024 ] New World Solutions (CSE: NEWS) (OTC: REGRF) Appoints Capital Markets Veteran Martin Tremblay to Board of Directors Newsmakers
- [ October 9, 2024 ] Leaders in The News: FuelCell Energy, WeightWatchers, NUBURU, New World Solutions News Feed
- [ October 9, 2024 ] NUBURU (NYSE: BURU) Partners with CDME at Ohio State University to Showcase the Unique Advantages of Blue Wavelength Lasers in Additive Manufacturing Newsmakers
- [ October 9, 2024 ] WeightWatchers (NASDAQ: WW) Adds Compounded GLP-1, Expanding Accessibility and Affordability of Weight Loss Medications Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.